Literature DB >> 31403863

Role of Intraperitoneal Therapy in the Initial Management of Ovarian Cancer.

Deborah K Armstrong1, Joan L Walker2.   

Abstract

Entities:  

Mesh：

Year:  2019        PMID： 31403863     DOI： 10.1200/JCO.19.00671

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  3 in total

Review 1.  History of intraperitoneal platinum drug delivery for ovarian cancer and its future applications.

Authors:  Franco Muggia; Andrea Bonetti
Journal:  Cancer Drug Resist       Date:  2021-06-19

2.  Can HIPEC be used against platinum-resistance and for inducing sensitivity to PARP inhibitors in ovarian cancer?

Authors:  Thales Paulo Batista; Graziela Zibetti Dal Molin
Journal:  Cancer Drug Resist       Date:  2020-07-10

3.  Phase II study of intraperitoneal submicron particle paclitaxel (SPP) plus IV carboplatin and paclitaxel in patients with epithelial ovarian cancersurgery.

Authors:  Sally Mullany; David Scott Miller; Katina Robison; Kimberly Levinson; Yi-Chun Lee; S Diane Yamada; Joan Walker; Maurie Markman; Alyson Marin; Peter Mast; Gere diZerega
Journal:  Gynecol Oncol Rep       Date:  2020-08-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.